Stock Price Movement and Market Context
On 4 Mar 2026, Vivo Bio Tech Ltd. recorded its lowest price in the past year at Rs.24.52, down 3.26% on the day. This decline extends an eight-day losing streak during which the stock has fallen by 10.37%. The stock’s performance today notably underperformed the Pharmaceuticals & Biotechnology sector by 1.71%, signalling relative weakness within its industry peer group.
Vivo Bio Tech is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning indicates sustained bearish sentiment and a lack of short- to long-term price support. In comparison, the Sensex, despite opening sharply lower by 1,710.03 points, managed a partial recovery to trade at 78,781.98, down 1.82%. The Sensex remains below its 50-day moving average, though the 50DMA is still above the 200DMA, suggesting mixed signals for the broader market.
Long-Term Performance and Relative Returns
Over the last twelve months, Vivo Bio Tech has delivered a negative return of 37.83%, significantly lagging the Sensex’s positive 7.97% gain over the same period. The stock’s 52-week high was Rs.44.70, underscoring the steep decline from its peak. Additionally, the company’s underperformance extends beyond the past year, with returns trailing the BSE500 index across one-year, three-month, and three-year horizons.
Perfect timing to enter! This Small Cap from IT - Software just turned profitable with growth momentum clearly building up. Get in before the broader market notices!
- - New profitability achieved
- - Growth momentum building
- - Under-the-radar entry
Financial Metrics and Profitability Trends
Vivo Bio Tech’s financial indicators reveal subdued profitability and growth. The company’s operating profits have grown at a compound annual growth rate (CAGR) of just 2.30% over the past five years, reflecting limited expansion in core earnings. The latest six-month period ending December 2025 saw a decline in profit after tax (PAT) to Rs.2.12 crore, representing a contraction of 64.96% compared to prior periods.
Return on Capital Employed (ROCE) for the half year stands at a low 7.95%, indicating modest efficiency in generating returns from capital investments. The average Return on Equity (ROE) is 6.60%, signalling relatively low profitability per unit of shareholders’ funds. Furthermore, the company’s ability to service debt is constrained, with an average EBIT to interest coverage ratio of 1.74, suggesting limited buffer to meet interest obligations.
Operational Efficiency and Working Capital
Working capital management metrics also point to challenges. The debtors turnover ratio for the half year is 3.54 times, one of the lowest levels recorded, implying slower collection cycles and potential liquidity pressures. These factors collectively contribute to the subdued financial health and market valuation of the company.
Valuation and Market Capitalisation
Despite the weak financial performance, Vivo Bio Tech’s valuation metrics indicate a relatively attractive price level. The stock trades at a discount compared to its peers’ historical averages, with an enterprise value to capital employed ratio of 0.8, which is considered very attractive. The company holds a market capitalisation grade of 4, reflecting its micro-cap status within the Pharmaceuticals & Biotechnology sector.
Shareholding Pattern
The majority of Vivo Bio Tech’s shares are held by non-institutional investors, which may influence liquidity and trading dynamics. Institutional participation appears limited, consistent with the stock’s current market profile and performance.
Vivo Bio Tech Ltd. or something better? Our SwitchER feature analyzes this micro-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Mojo Score and Analyst Ratings
Vivo Bio Tech currently holds a Mojo Score of 26.0, categorised as a Strong Sell. This rating was upgraded from Sell to Strong Sell on 19 Jan 2026, reflecting deteriorating fundamentals and market sentiment. The score incorporates multiple factors including profitability, growth, debt servicing ability, and valuation metrics, all of which have shown weakness in recent assessments.
Sector and Market Comparison
Within the Pharmaceuticals & Biotechnology sector, Vivo Bio Tech’s performance contrasts with broader sector trends. While the sector has seen mixed results, the stock’s sustained decline and underperformance relative to sector indices highlight company-specific pressures. Additionally, other indices such as NIFTY Realty and S&P BSE Realty also hit 52-week lows today, indicating pockets of weakness across the market.
Summary of Key Concerns
The stock’s fall to Rs.24.52 marks a critical price level, underscored by a combination of weak profitability, limited growth, constrained debt servicing capacity, and subdued operational efficiency. The persistent decline over eight consecutive trading sessions and underperformance relative to sector and market benchmarks further emphasise the challenges faced by Vivo Bio Tech.
Valuation Considerations
Despite these concerns, the stock’s valuation metrics suggest it is trading at a discount relative to peers, with a low enterprise value to capital employed ratio. This valuation reflects the market’s cautious stance given the company’s financial profile and recent performance trends.
Conclusion
Vivo Bio Tech Ltd.’s new 52-week low at Rs.24.52 encapsulates a period of sustained price weakness amid subdued financial results and challenging market conditions. The stock’s technical and fundamental indicators point to ongoing pressures, with limited signs of near-term improvement in profitability or growth metrics. Investors and market participants will continue to monitor the company’s financial disclosures and sector developments for further insights.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
